Skip to main content
SpringerLink
Log in

Taxane-Based Chemotherapy for Prostate Cancer

  • Chapter
Prostate Cancer

Part of the book series: Contemporary Cancer Research ((CCR))

Abstract

Hormone-refractory prostate cancer (HRPC), defined as progression of disease in the setting castrate testosterone levels, is associated with significant morbidity and a dismal prognosis. Historically, the paradigm for treatment of HRPC focused on palliation because of the lack of available therapies that improved survival. The taxanes, chemotherapeutic agents that stabilize microtubules, thereby preventing further cell division, demonstrated efficacy in the treatment of HRPC in phase I and phase II studies. In addition, taxane-based therapies palliated disease complications with minimal toxicity. Two randomized studies, SWOG 9916 and TAX 327, were the first trials to establish the survival benefit of docetaxel for men with progressive HRPC. As the literature describing the benefit of taxane-based chemotherapy for metastatic disease has grown, the role of these therapies for neoadjuvant and adjuvant treatment of high-risk localized disease are being investigated. The future of taxanebased treatment lies in combination strategies with biological and targeted therapy, including agents targeting angiogenesis, the endothelin receptor, and other signal pathways to help overcome drug resistance and improve clinical outcomes for patients with HRPC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal, A., Murray, T., Ward, E., et al. (2005).Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10–30.

    Article  PubMed  Google Scholar 

  2. Beedassy, A., and Cardi, G. (1999). Chemotherapy in advanced prostate cancer. Semin. Oncol. 26(4), 428–438.

    PubMed  CAS  Google Scholar 

  3. Kupelian, P. A., Elshaikh, M., Reddy, C. A., Zippe, C., and Klein E. A. (2002). Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J. Clin. Oncol. 20(16), 3376–3385.

    Article  PubMed  Google Scholar 

  4. Bhandari, M. S., Petrylak, D. P., and Hussain, M. (2005). Clinical trials in metastatic prostate cancer-has there been real progress in the past decade? Eur. J. Cancer 41(6), 941–953.

    Article  PubMed  Google Scholar 

  5. Coen, J. J., Zietman, A. L., Thakral, H., and Shipley, W. U. (2002). Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J. Clin. Oncol. 20(15), 3199–3205.

    Article  PubMed  Google Scholar 

  6. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. (2001). Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 28(3), 555–565.

    Article  PubMed  CAS  Google Scholar 

  7. D’Amico, A. V., Whittington, R., Malkowicz, S. B., et al. (1998).Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11), 969–974.

    Article  PubMed  CAS  Google Scholar 

  8. Petrylak, D. P. (2002). Chemotherapy for androgen-independent prostate cancer. Semin. Urol. Oncol. 20(3 Suppl. 1), 31–35.

    Article  PubMed  Google Scholar 

  9. Auclerc, G., Antoine, E. C., Cajfinger, F., Brunet-Pommeyrol, A., Agazia, C., and Khayat, D. (2000). Management of advanced prostate cancer. Oncologist 5(1), 36–44.

    Article  PubMed  CAS  Google Scholar 

  10. Catalona, W. J. (1994). Management of cancer of the prostate. N. Engl. J. Med. 331(15), 996–1004.

    Article  PubMed  CAS  Google Scholar 

  11. Berry, W., Dakhil, S., and Modiano, M. (2002). Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J. Urol. 168, 2439–2443.

    Article  PubMed  CAS  Google Scholar 

  12. Tannock, I. F., Osoba, D., Stockler, M. R., et al. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756–1764.

    PubMed  CAS  Google Scholar 

  13. Kantoff, P. W., Halabi, S., Conaway, M., et al. (1999). Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. Aug; 17(8), 2506-2513.

    Google Scholar 

  14. Chi, K. N. (2005). Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J. Urol. 23(1), 33–37.

    Article  PubMed  CAS  Google Scholar 

  15. Reed, J. C. (1997). Double identity for proteins of the Bcl-2 family. Nature 387(6635), 773–776.

    Article  PubMed  CAS  Google Scholar 

  16. Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., and Reed, J. C. (1998). Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. Sci. USA 95(9), 4997–5002.

    Article  PubMed  CAS  Google Scholar 

  17. Colombel, M., Symmans, F., Gil, S., et al. (1993). Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143(2), 390–400.

    PubMed  CAS  Google Scholar 

  18. McDonnell, T. J., Navone, N. M., Troncoso, P., et al. (1997). Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol. 157(2), 569–574.

    Article  PubMed  CAS  Google Scholar 

  19. McDonnell, T. J., Troncoso, P., Brisbay, S. M., et al. (1992). Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52(24), 6940–6944.

    PubMed  CAS  Google Scholar 

  20. Bubendorf, L., Sauter, G., Moch, H., et al. (1996). Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol. 148(5), 1557–1565.

    PubMed  CAS  Google Scholar 

  21. Raffo, A. J., Perlman, H., Chen, M. W., Day, M. L., Streitman, J. S., and Buttyan, R. (1995). Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55(19), 4438–4445.

    PubMed  CAS  Google Scholar 

  22. Tu, S. M., McConnell, K., and Marin, M. C. (1995). Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett. 93, 147–155.

    Article  PubMed  CAS  Google Scholar 

  23. Haldar, S., Chintapalli, J., and Croce, C. M. (1996). Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56(6), 1253–1255.

    PubMed  CAS  Google Scholar 

  24. Dahllof, B., Billstrom, A., Cabral, F., and Hartley-Asp, B. (1993). Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53(19), 4573–4581.

    PubMed  CAS  Google Scholar 

  25. Stearns, M. E. and Tew, K. D. (1985). Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 45(8), 3891–3897.

    PubMed  CAS  Google Scholar 

  26. Pienta, K. J. and Lehr, J. E. (1993). Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J. Urol. 149(6), 1622–1625.

    PubMed  CAS  Google Scholar 

  27. Speicher, L. A., Barone, L. R., Chapman A. E., et al. (1994). P-glycoprotein binding and modulation of the multidrugresistant phenotype by estramustine. J. Natl. Cancer Inst. 86(9), 688–694.

    Article  PubMed  CAS  Google Scholar 

  28. Yagoda, A. and Petrylak, D. (1993). Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71(3 Suppl.), 1098–1109.

    Article  PubMed  CAS  Google Scholar 

  29. Speicher, L. A., Barone, L., and Tew, K. D. (1992). Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 52(16), 4433–4440.

    PubMed  CAS  Google Scholar 

  30. Kreis, W., Budman, D. R., and Calabro, A. (1997). Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br. J. Urol. 79(2), 196–202.

    PubMed  CAS  Google Scholar 

  31. Hussain, M. H., Pienta, K. J., Redman, B. G., Cummings, G. D., and Flaherty, L. E. (1994). Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 74(1), 100–103.

    Article  PubMed  CAS  Google Scholar 

  32. Pienta, K. J., Redman, B., Hussain, M., et al. (1994). Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. 12(10), 2005–2012.

    PubMed  CAS  Google Scholar 

  33. Hudes, G., Einhorn, L., Ross, E., et al. (1999). Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J. Clin. Oncol. 17(10), 3160–3166.

    PubMed  CAS  Google Scholar 

  34. Roth, B. J., Yeap, B. Y., Wilding, G., Kasimis, B., McLeod, D., and Loehrer, P. J. (1993). Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72(8), 2457–2460.

    Article  PubMed  CAS  Google Scholar 

  35. Trivedi, C., Redman, B., Flaherty, L. E., et al. (2000). Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 89(2), 431–436.

    Article  PubMed  CAS  Google Scholar 

  36. Picus, J. and Schultz, M. (1999). Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. 26(5 Suppl. 17), 14–18.

    PubMed  CAS  Google Scholar 

  37. Friedland D., Cohen J., Miller R., Jr., et al. (1999). A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol. 26(5 Suppl. 17), 19–23.

    PubMed  CAS  Google Scholar 

  38. Beer, T. M., Pierce, W. C., Lowe, B. A., and Henner, W. D. (2001). Phase II trial of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann. Oncol. 12, 1273–1279.

    Article  PubMed  CAS  Google Scholar 

  39. Berry, W., Dakhil, S., Gregurich, M. A., and Asmar, L. (2001). Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin. Oncol. 28(Suppl. 15), 8–15.

    Article  PubMed  CAS  Google Scholar 

  40. Gravis, G., Bladou, F., Salem, N., et al. (2003). Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 98(8), 1627–1634.

    Article  PubMed  CAS  Google Scholar 

  41. Hudes, G. R., Obasaju, C., Chapman, A., Gallo, J., McAleer, C., and Greenberg, R. (1995). Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin. Oncol. 22(3 Suppl. 6), 6–11.

    PubMed  CAS  Google Scholar 

  42. Hudes, G. R., Nathan, F., Khater, C., et al. (1997). Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 15(9), 3156–3163.

    PubMed  CAS  Google Scholar 

  43. Kuzel, T. M., Kies, M. S., Wu, N., Hsieh, Y. C., and Rademaker, A. W. (2002). Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer. Cancer Invest. 20(5-6), 634–643.

    Article  PubMed  CAS  Google Scholar 

  44. Vaishampayan, U., Fontana, J., Du, W., and Hussain, M. (2002). An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology 60(6), 1050–1054.

    Article  PubMed  Google Scholar 

  45. Vaughn, D. J., Brown, A. W., Jr., and Harker, W. G., et al. (2004). Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Cancer 100(4), 746–750.

    Article  PubMed  CAS  Google Scholar 

  46. Kelly, W. K., Curley, T., Slovin, S., et al. (2001). Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol. 19(1), 44–53.

    PubMed  CAS  Google Scholar 

  47. Smith, D. C., Esper, P., Strawderman, M., Redman, B., and Pienta, K. J. (1999). Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. 17(6), 1664–1671.

    PubMed  CAS  Google Scholar 

  48. Chay, C. and Smith, D. C. (2001). Adjuvant and neoadjuvant therapy in prostate cancer. Semin. Oncol. 28(1), 3–12.

    Article  PubMed  CAS  Google Scholar 

  49. Berry, W. R., Hathorn, J. W., Dakhil, S. R., et al. (2004). Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin. Prostate Cancer 3(2), 104–111.

    PubMed  CAS  Google Scholar 

  50. Petrylak, D. P., Macarthur, R. B., O’Connor, J., et al. (1999).Phase I trial of docetaxel with estramustine in androgenindependent prostate cancer. J. Clin. Oncol. 17(3), 958–967.

    PubMed  CAS  Google Scholar 

  51. Kreis, W., Budman, D. R., Fetten, J., Gonzales, A. L., Barile, B., and Vinciguerra, V. (1999). Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann. Oncol. 10(1), 33–38.

    Article  PubMed  CAS  Google Scholar 

  52. Natale, R. B. and Zaretsky, S. L. (1999). Phase I/II trial of estramustine (E) and Taxotere (T) in patients with metastatic hormone-refractory prostate cancer (HRPC). Pr. Am. Soc. Clin. Oncol. 348a(18), 1343 (abstr).

    Google Scholar 

  53. Petrylak, D., Shelton, G., England-Owen, C., Pfaff, C., Bagliella, E., and Diuleo, R. (2000). Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine phosphate (EMP) in patients (Pts) with hormone refractory prostate cancer (HRPC): updated preliminary analysis. Pr. Am. Soc. Clin. Oncol. 19(334a), 1312 (abstr).

    Google Scholar 

  54. Savarese, D., Taplin, M. E., Halabi, S., Hars, V., Kreis, W., and Vogelzang, N. (1999). A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin. Oncol. 26(5 Suppl. 17), 39–44.

    PubMed  CAS  Google Scholar 

  55. Sinibaldi, V. J., Carducci, M. A., Moore-Cooper, S., Laufer, M., Zahurak, M., and Eisenberger, M. A. (2002). Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94(5), 1457–1465.

    Article  PubMed  CAS  Google Scholar 

  56. Kosty, M. P., Ferreira, A., and Byrntesen, T. (2001). Weekly docetaxel and low-dos estramustine phosphate in hormone-refractory prostate cancer: a phase II study. Proc. Am. Soc. Clin. Oncol. 20(152b) 2360 (abstr).

    Google Scholar 

  57. Weitzman, A. L., Shelton, G., Zuech, N., et al. (2000). Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J. Urol. 163(3), 834–837.

    Article  PubMed  CAS  Google Scholar 

  58. Petrylak, D. P., Tangen, C. M., Hussain, M. H., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520.

    Article  PubMed  CAS  Google Scholar 

  59. Crawford, E. D., Pauler, D. K., and Tangen, C. M. (2004). Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): data from Southwest Oncology Group Study S9916. Pr. Am. Soc. Clin. Oncol. 23(4505), 382.

    Google Scholar 

  60. Tannock, I. F., deWit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512.

    Article  PubMed  CAS  Google Scholar 

  61. Smith, D. S., Humphrey, P. A., and Catalona, W. J. (1997). The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer 80(9), 1852–1856.

    Article  PubMed  CAS  Google Scholar 

  62. Soh, S., Kattan, M. W., Berkman, S., Wheeler, T. M., and Scardino, P. T. (1997). Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J. Urol. 157(6), 2212–2218.

    Article  PubMed  CAS  Google Scholar 

  63. Pettaway, C. A., Pisters, L. L., Troncoso, P., et al. (2000). Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J. Clin. Oncol. Mar;18(5), 1050-1057.

    Google Scholar 

  64. Scolieri, M. J., Altman, A., and Resnick, M. I. (2000). Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J. Urol. 164(5), 1465–1472.

    Article  PubMed  CAS  Google Scholar 

  65. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr., and Puras-Baez, A. (1995). Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 154(2 Pt 1), 424–428.

    PubMed  CAS  Google Scholar 

  66. Goldenberg, S. L., Klotz, L. H., Srigley, J., et al. (1996). Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J. Urol. 156(3), 873–877.

    Article  PubMed  CAS  Google Scholar 

  67. Aus, G., Abrahamsson, P. A., Ahlgren, G., et al. (1998). Hormonal treatment before radical prostatectomy: a 3-year followup. J. Urol. 159(6), 2013–2016; discussion 2016-2017.

    Article  PubMed  CAS  Google Scholar 

  68. D’Amico, A. (2001). Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 58(2 Suppl. 1), 78–82.

    Article  PubMed  CAS  Google Scholar 

  69. Clark, P. E., Peereboom, D. M., Dreicer, R., Levin, H. S., Clark, S. B., and Klein, E.A. (2001). Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57(2), 281–285.

    Article  PubMed  CAS  Google Scholar 

  70. Hussain, M., Smith, D. C., El-Rayes, B. F., et al. (2003). Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 61(4), 774–780.

    Article  PubMed  Google Scholar 

  71. Ko, Y. J., Dewolf, W., Olumi, A., Sesterhenn, I. A., Upton, M., and Bubley, G. J. (2002). Neoadjuvant chemo-hormonal therapy followed by radical prostatectomy for high risk prostate cancer. Am. Soc. Clin. Oncol. 21, 2645.

    Google Scholar 

  72. Oh, W. K. (2003). The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. J. Urol. 170, S28–S34.

    Article  PubMed  Google Scholar 

  73. Smith, D. C., Chay, C. H., Dunn, R. L, et al. (2003). Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98(2), 269–276.

    Article  PubMed  CAS  Google Scholar 

  74. Vaishampayan, U. and Hussain, M. (2000). Adjuvant chemo-/hormonal therapy trials for locally advanced prostate cancer. Curr. Oncol. Rep. 2(5), 402–408.

    Article  PubMed  CAS  Google Scholar 

  75. Makarovskiy, A. N., Siryaporn, E., Hixson, D. C., and Akerley, W. (2002). Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol. Life Sci. 59(7), 1198–1211.

    Article  PubMed  CAS  Google Scholar 

  76. Ranganathan, S., Dexter, D. W., Benetatos, C. A., Chapman, A. E., Tew, K. D., and Hudes, G. R. (1996). Increase of beta(III)-and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 56(11), 2584–2589.

    PubMed  CAS  Google Scholar 

  77. Wahl, A. F., Donaldson, K. L., Fairchild, C., et al. (1996). Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2(1), 72–79.

    Article  PubMed  CAS  Google Scholar 

  78. Lebedeva, I., Rando, R., Ojwang, J., Cossum, P., and Stein, C. A. (2000). Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 60(21), 6052–6060.

    PubMed  CAS  Google Scholar 

  79. Gleave, M. E., Miayake, H., Goldie, J., Nelson, C., and Tolcher, A. (1999). Targeting bcl-2 gene to delay androgenindependent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 54(6A Suppl), 36–46.

    Article  PubMed  CAS  Google Scholar 

  80. Blutt, S. E., McDonnell, T. J., Polek, T. C., and Weigel, N. L. (2000). Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141(1), 10–17.

    Article  PubMed  CAS  Google Scholar 

  81. Hershberger, P. A., Yu, W. D., Modzelewski, R. A., Rueger, R. M., Johnson, C. S., and Trump, D. L. (2001). Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxelinduced apoptosis. Clin. Cancer Res. 7(4), 1043–1051.

    PubMed  CAS  Google Scholar 

  82. Beer, T. M., Eilers, K. M., and Garzotto, M. (2003). Weekly high-dose calcitriol and docetaxel in metastatic androgenindependent prostate cancer. J. Clin. Oncol. 21, 123–128.

    Article  PubMed  CAS  Google Scholar 

  83. Beer, T. M., Ryan, C. W., Venner, P. M., et al. (2005). Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc. Am. Soc. Clin. Oncol. 4516 (abstract).

    Google Scholar 

  84. Ferrer, F. A., Miller, L. J., Lindquist, R., et al. (1999). Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54(3), 567–572.

    Article  PubMed  CAS  Google Scholar 

  85. Ferrer, F. A., Miller, L. J., Andrawis, R. I., et al. (1998). Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51(1), 161–167.

    Article  PubMed  CAS  Google Scholar 

  86. Ferrer, F. A., Miller, L. J., Andrawis, R. I., et al. (1997). Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol. 157(6), 2329–2333.

    Article  PubMed  CAS  Google Scholar 

  87. Duque, J. L., Loughlin, K. R., Adam, R. M., Kantoff, P. W., Zurakowski, D., and Freeman, M. R. (1999). Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54(3), 523–527.

    Article  PubMed  CAS  Google Scholar 

  88. Bok, R. A., Halabi, S., Fei, D. T., et al. (2001). Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 61(6), 2533–2536.

    PubMed  CAS  Google Scholar 

  89. George, D. J., Halabi, S., Shepard, T. F., et al. (2001). Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 7(7), 1932–1936.

    PubMed  CAS  Google Scholar 

  90. Ng, S. S., MacPherson, G. R., Gutschow, M., Eger, K., and Figg, W. D. (2004). Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin. Cancer Res. 10(12 Pt 1), 4192–4197.

    Article  PubMed  CAS  Google Scholar 

  91. Figg, W. D., Dahut, W., Duray, P., et al. (2001). A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7(7), 1888–1893.

    PubMed  CAS  Google Scholar 

  92. Figg, W. D., Arlen, P., Gulley, J., et al. (2001). A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin. Oncol. 28(4 Suppl. 15), 62–66.

    Article  PubMed  CAS  Google Scholar 

  93. Retter, A. S., Ando, Y., Price, D. K., et al. (2005). Follow-up analysis of a randomized phase II study of docetaxel (D) and thalidomide (T) in androgen-independent prostate cancer (AIPC): updated survival data and stratification by CYP2C19 mutational status. Proc. Am. Soc. Clin. Oncol. 265 (2005 Prostate Cancer Symposium abstract).

    Google Scholar 

  94. Picus, J., Halabi, S., and Rini, B. I. (2004). The use of bevacizumab. Am. Soc. Clin. Oncol. 22, 1578A.

    Google Scholar 

  95. Carducci, M. A., Padley, R. J., Breul, J., et al. (2003). Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J. Clin. Oncol. 21(4), 679–689.

    Article  PubMed  CAS  Google Scholar 

  96. Carducci, M. A., Nelson, J. B., and Saad, F. (2004). Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase III study. Pr. Am. Soc. Clin. Oncol. 222(41S), abstr 4508.

    Google Scholar 

  97. Tolcher, A. W., Chi, K., Kuhn, J., et al. (2005). A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 11(10), 3854–3861.

    Article  PubMed  CAS  Google Scholar 

  98. Tolcher, A. W., Kuhn, J., Schwartz, G., et al. (2004). A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 10(15), 5048–5057.

    Article  PubMed  CAS  Google Scholar 

  99. Haas, N., Roth, B., Garay, C., et al. (2001). Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 58(1), 59–64.

    Article  PubMed  CAS  Google Scholar 

  100. Athanasiadis, A., Tsavdaridis, D., Rigatos, S. K., Athanasiadis, I., Pergantas, N., and Stathopoulos, G. P. (2003). Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination. Anticancer Res. 23(3C), 3085–3088.

    PubMed  CAS  Google Scholar 

  101. Hudes, G. R., Nathan, F. E., Khater, C., et al. (1995). Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol. 22(5 Suppl. 12), 41–45.

    PubMed  CAS  Google Scholar 

  102. Petrylak, D. P., Macarthur, R., O’Connor, J., et al. (1999). Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin. Oncol. 26(5 Suppl 17), 28–33.

    PubMed  CAS  Google Scholar 

  103. Sitka Copur, M., Ledakis, P., Lynch, J., et al. (2001). Weekly docetaxel and estramustine in patients with hormonerefractory prostate cancer. Semin Oncol. 28(4 Suppl. 15), 16–21.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York Presbyterian Hospital, New York, NY

    Supriya G. Mohile MD, MS & Daniel P. Petrylak MD

Authors
  1. Supriya G. Mohile MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel P. Petrylak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Emory University School of Medicine, Atlanta, GA

    Leland W. K. Chung PhD

  2. Johns Hopkins University School of Medicine, Baltimore, MD

    William B. Isaacs PhD

  3. Prostate Cancer Foundation, Santa Monica, CA

    Jonathan W. Simons MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Mohile, S.G., Petrylak, D.P. (2007). Taxane-Based Chemotherapy for Prostate Cancer. In: Chung, L.W.K., Isaacs, W.B., Simons, J.W. (eds) Prostate Cancer. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59745-224-3_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-224-3_23

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-696-2

  • Online ISBN: 978-1-59745-224-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation